Explore every episode of the podcast CME in Minutes: Education in Primary Care

Please visit answersincme.com/860/04572-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Cedric James Franklin Rutland, MD, FCCP; Stephanie Christenson, MD, MAS; and Surya P. Bhatt, MD, MSPH. In this activity, experts in chronic obstructive pulmonary disease (COPD) discuss the role of eosinophil testing, biologic therapies, and strategies for individualized, guideline-based treatment. Upon completion of this activity, participants should be better able to: Recognize the role of eosinophils and eosinophilic testing in COPD; Select biologic therapies for appropriate patients with eosinophilic COPD, based on the latest evidence and guidance; and Collaborate with an interdisciplinary team to integrate the latest guideline recommendations into individualized treatment plans tailored to patient and disease characteristics. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/860/04572-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Cedric James Franklin Rutland, MD, FCCP; Stephanie Christenson, MD, MAS; and David Mannino, MD, FCCP, FERS. In this activity, experts in chronic obstructive pulmonary disease (COPD) discuss the role of eosinophil testing, biologic therapies, and strategies for individualized, guideline-based treatment. Upon completion of this activity, participants should be better able to: Recognize the role of eosinophils and eosinophilic testing in COPD; Select biologic therapies for appropriate patients with eosinophilic COPD, based on the latest evidence and guidance; and Collaborate with an interdisciplinary team to integrate the latest guideline recommendations into individualized treatment plans tailored to patient and disease characteristics. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/ZSN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Wanda Phipatanakul, MD, MS. In this activity, an expert in pediatric asthma discusses how to identify type 2 inflammation and tailor biologic therapy for pediatric patients with asthma. Upon completion of this activity, participants should be better able to: Identify the impact of type 2 inflammation on lung function in pediatric patients with asthma; Recognize best practices for incorporating biologics into the treatment of type 2 inflammatory pediatric asthma; and Outline the role of multidisciplinary teams in optimizing outcomes for pediatric patients with type 2 inflammatory asthma. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/JJK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Rajsekar (Raj) Rajaraman, MD, MS. In this activity, an expert in pediatric neurology discusses the diagnosis and management of CDKL5 deficiency disorder. Upon completion of this activity, participants should be better able to: Describe key clinical characteristics that contribute to the burden of CDKL5 deficiency disorder (CDD); Evaluate the role of timely diagnosis in influencing care decisions for individuals with CDD; and Outline therapeutic approaches for managing seizures associated with CDD.

Please visit answersincme.com/860/104092969-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO; and Jesus Berdeja, MD. In this activity, experts in hematology-oncology discuss the evolving role of cereblon E3 ligase modulators (CELMoDs) in patients with relapsed/refractory multiple myeloma (RRMM). Upon completion of this activity, participants should be better able to: Identify the role of CELMoDs in the treatment of patients with RRMM. Utilize evidence-based practical strategies for the management of key adverse events associated with CELMoDs in patients with RRMM. Apply key considerations to support the integration of CELMoDs into the treatment paradigm for patients with RRMM.

Please visit answersincme.com/860/CME-26-207477-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vallerie V. McLaughlin, MD; and Richard Channick, MD. In this activity, experts in pulmonary arterial hypertension (PAH) discuss strategies for personalized risk-based intensification of therapy for patients with PAH. Upon completion of this activity, participants should be better able to: Describe the rationale for risk-based treatment intensification strategies in patients with PAH. Identify clinical indicators warranting escalation of therapy in patients with intermediate- or high-risk PAH. Outline an evidence-based, personalized approach to integrating novel add-on therapies into treatment plans for patients with PAH. undefined In this activity, experts in pulmonary arterial hypertension (PAH) discuss strategies for personalized risk-based intensification of therapy for patients with PAH.

Please visit answersincme.com/860/014832-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Anne E. O'Donnell, MD; andPatrick Flume, MD. In this activity, experts in bronchiectasis discuss best practices for identifying, diagnosing, and treating CF and non-CF bronchiectasis. Upon completion of this activity, participants should be better able to:Distinguish between underlying causes of bronchiectasis that provide the rationale for targeting neutrophil inflammation. Outline recommended multidisciplinary strategies to promptly recognize and diagnose bronchiectasis. Describe the design and eligibility criteria of ongoing trials evaluating neutrophil-targeted therapies for bronchiectasis. This session is supported by Boehringer Ingelheim Pharmaceuticals, Inc. Exhibitors and supporters of NACFC include manufacturers of CF drugs, medical device companies, pharmacies, hospitals, and other related organizations. The Cystic Fibrosis Foundation does not support nor endorse the products or services of NACFC 2026 exhibitors and supporters.

Please visit answersincme.com/860/160204757-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Karen P. Acker, MD; and Donna Hallas, PhD, PPCNP-PC, CPNP, PMHS, FAANP, FAAN. In this activity, experts in RSV prevention discuss the latest evidence and practical strategies for implementing immunoprophylaxis and coordinating caregiver counseling across the care continuum. Upon completion of this activity, participants should be better able to: Discuss the rationale for RSV immunoprophylaxis for preventing RSV disease in early infancy. Integrate guideline recommendations into shared clinical decision-making for the prevention of RSV in infants. Outline the complementary roles of pre- and postnatal clinicians in coordinating RSV immunization counseling across the care continuum. Implement coordinated communication strategies to support caregiver decision-making about RSV prevention. This symposium is not sponsored, endorsed or accredited by the American Academy of Pediatrics.

Please visit answersincme.com/CJF860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Manuel Rodriguez-Justo, MBBCh, MSc, MD, FRCPath; and Elizabeth Smyth, MD, FRCP. In this activity, experts in oncology and pathology discuss the impact of claudin 18.2 (CLDN18.2) tests and treatments for patients with advanced gastric or gastroesophageal junction cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for CLDN18.2 testing in patients with advanced gastric and gastroesophageal junction cancers (GC/GEJC); Review the potential clinical impact of emerging CLDN18.2-targeted antibody-drug conjugates (ADCs) for the treatment of GC/GEJC; and Outline evidence-based, emerging strategies to optimize outcomes in patients with advanced GC/GEJC.

Please visit answersincme.com/QRE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Theresa W. Guilbert, MD, MS. In this activity, an expert in childhood asthma discusses the use of biologics for moderate to severe pediatric asthma. Upon completion of this activity, participants should be better able to: Identify the impact of type 2 inflammation on lung function in pediatric patients with asthma; Recognize best practices for incorporating biologics into the treatment of type 2 inflammatory pediatric asthma; and Review the clinical profiles of biologic therapies for type 2 inflammatory asthma in pediatric patients. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/MSM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ritu Salani, MD; and Courtney Arn, CNP. In this activity, experts in gynecological oncology discuss antibody-drug conjugates (ADCs) in ovarian, cervical, and endometrial cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for using ADCs in previously treated patients with gynecologic cancers; Assess the safety and tolerability evidence for approved ADC therapies in gynecologic cancers; Formulate management strategies for adverse events associated with ADC treatment of ovarian, cervical, and endometrial cancers; and Outline patient-centered approaches to facilitate adherence with ADC therapy.

Please visit answersincme.com/FSP860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jay N. Yepuri, MD, MS, FACG, FTSGE. In this activity, an expert in gastroenterology discusses molecular prognostics tests that predict the risk of progression from Barrett’s esophagus (BE) to esophageal adenocarcinoma (EAC). Upon completion of this activity, participants should be better able to: Describe the limitations of traditional approaches to predicting risk of progression to EAC for patients with BE; Review the evolving role of advanced molecular prognostic tests in assessing risk of progression to EAC in patients with BE; and Outline multidisciplinary strategies to integrate advanced molecular prognostic tests into the management of patients with BE.

Please visit answersincme.com/WAY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Elizabeth O'Donnell, MD. In this activity, an expert in multi-cancer early detection (MCED) discusses strategies to apply MCED testing into everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the benefits and risks of MCED testing; and Outline patient-centered strategies to appropriately incorporate MCED testing into the primary care setting.

Please visit answersincme.com/BVK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jesus E. Pina-Garza, MD. In this activity, an expert in epilepsy discusses recognizing seizure emergencies, selecting appropriate rescue treatments and routes of administration, and developing individualized seizure action plans. Upon completion of this activity, participants should be better able to: Define seizure emergencies based on expert consensus to support accurate treatment decisions; Evaluate approved therapeutic approaches for the management of seizure clusters in the home/community setting; and Identify strategies to support the timely use of acute seizure medications through patient-centered seizure action plans.

Please visit answersincme.com/860/cvdprostate-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Michael Cookson, MD; Alicia Morgans, MD, MPH; and Avirup Guha, MD, MBBS, MPH, FAHA, FACC, FESC, FICOS. In this activity, experts in prostate cancer discuss cardiovascular risk in patients receiving androgen-deprivation therapy (ADT). Upon completion of this activity, participants should be better able to: Evaluate the impacts of prostate cancer and ADT on cardiovascular risk; Translate the latest research for cardiovascular management of patients on ADT to clinical practice; and Design personalized treatment approaches to optimize ADT across treatment settings.

Please visit answersincme.com/NHB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Zev Wainberg, MD. In this activity, an expert in oncology discusses the use of TROP2-directed antibody-drug conjugates (ADCs) across solid tumors. Upon completion of this activity, participants should be better able to: Review the rationale for targeting TROP2 with antibody-drug conjugates (ADCs) across tumor stages and settings; Evaluate the clinical profiles of available and emerging TROP-targeting ADCs across tumor stages and settings; and Apply evidence-based strategies to recognize and monitor treatment-related adverse events (TRAEs) associated with ADCs.

Please visit answersincme.com/TZA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by James E. Galvin, MD, MPH. In this activity, an expert in Alzheimer’s disease (AD) discusses treatment of early AD with anti-amyloid therapies. Upon completion of this activity, participants should be better able to: Review the latest advances in anti-amyloid therapies for the treatment of early Alzheimer’s disease (AD; Assess the current evidence on anti-amyloid therapies, including maintenance strategies, for the treatment of early AD; and Outline strategies to integrate the latest advances in anti-amyloid therapies to practice to improve long-term outcomes for patients with early AD.

Please visit answersincme.com/BHT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sara Stafford, MDCM, FRCPC and Gihane Zarifa, MD, CCFP, FCFP, MSc. In this activity, experts in family medicine and endocrinology discuss the role of oral glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) in personalized type 2 diabetes (T2D) management. Upon completion of this activity, participants should be better able to: Discuss individualized, guideline-informed management strategies for T2D that address glycemic control, weight, and patient-specific factors; Differentiate key pharmacologic, administration, and tolerability characteristics of oral GLP-1 RAs to support patient counseling in T2D; and Interpret clinical evidence for approved and emerging oral GLP-1 RAs to inform their potential role in addressing gaps in T2D management.

Please visit answersincme.com/RVH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vivien Brown, MDCM, CCFP, FCFP, MSCP. In this activity, an expert in menopause management in primary care discusses identification and treatment of menopause-related vasomotor symptoms (VMS). Upon completion of this activity, participants should be better able to: Integrate communication about menopause and VMS into routine patient encounters; Review treatment options for moderate to severe VMS, including NK receptor antagonists, with patients using a shared decision-making approach; and Formulate strategies for optimally monitoring patients who are receiving NK receptor antagonists for menopause-related VMS.

Please visit answersincme.com/860/MED-RESP-04317-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Cecelia Damask, DO; Zara M. Patel, MD; Maria Colandrea, DNP, NP-C, CORLN, FAANP; and Dan Shaltanis. In this activity, experts in chronic rhinosinusitis with nasal polyps discuss the latest evidence and practical strategies for optimizing the use of biologic therapies and delivering patient-centered care. Upon completion of this activity, participants should be better able to: Review guideline recommendations for the use of biologic therapies to treat patients with chronic rhinosinusitis with nasal polyps (CRSwNP); Differentiate among biologic therapies for patients with CRSwNP based on clinical evidence; and Outline strategies to optimize the holistic management of CRSwNP.

Please visit answersincme.com/SJN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jewel M. Kling, MD, MPH and Genevieve Neal-Perry, MD, PhD. In this activity, experts in menopause management discuss unmet therapeutic needs, emerging evidence for neurokinin (NK) receptor antagonists, and patient-focused strategies for managing menopause-associated vasomotor symptoms (VMS). Upon completion of this activity, participants should be better able to: Recognize unmet therapeutic needs among patients with menopause-associated VMS; Assess the evidence for nonhormonal therapies targeting NK receptors in the treatment of menopause-associated VMS; and Formulate patient-focused strategies for the optimal use of NK receptor antagonists for menopause-associated VMS.

Please visit answersincme.com/JKK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alison J. Birtle, FRCP, FRCR, MD; and Niklas Klümper, MD. In this activity, experts in oncology discuss systemic therapies for locally advanced and metastatic urothelial carcinoma. Upon completion of this activity, participants should be better able to: Assess the evidence for recommended systemic treatment regimens for patients with LA/mUC in the context of treatment guidelines; Propose appropriate patient assessment strategies to guide systemic therapy decisions; and Formulate individualized treatment strategies to optimize outcomes for patients with LA/mUC using recommended first-line systemic treatments.

Please visit answersincme.com/BWG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ferhina Ali, MD, MPH, FASRS. In this activity, an expert in retinal diseases discusses integrating clinical trial and real-world evidence into the use of newer-generation anti–vascular endothelial growth factor (VEGF) agents. Upon completion of this activity, participants should be better able to: Review the role of different types of data in informing management of retinal diseases; Assess clinical trial data and real-world evidence supporting the use of newer-generation anti-VEGF agents for retinal diseases; and Propose treatment plans for the management of retinal diseases based on clinical trial data and real-world evidence.

Please visit answersincme.com/ZGK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Amer Zeidan, MBBS, MHS. In this activity, an expert in myelodysplastic syndromes (MDS) discusses approaches to optimize management of anemia in lower-risk MDS. Upon completion of this activity, participants should be better able to: Translate the latest clinical trial data to the management of patients with lower-risk MDS; Evaluate evidence-based strategies for optimizing the use of available agents in lower-risk MDS; and Design treatment plans that effectively sequence available therapies in patients with lower-risk MDS.

Please visit answersincme.com/ZYD860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by April W. Armstrong, MD, MPH. In this activity, an expert in dermatology discusses best practices to diagnose and manage bullous pemphigoid (BP). Upon completion of this activity, participants should be better able to: Review the process for diagnosing patients with BP; Assess the evidence for the use of biologics targeting type 2 inflammation in the treatment of BP; and Outline the clinical implications of the evidence for the treatment of BP with biologics targeting type 2 inflammation.

Please visit answersincme.com/AQE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nirmala Gonsalves, MD, AGAF, FACG. In this activity, an expert in esophageal gastroenterology, discusses strategies for pharmacological treatment of eosinophilic esophagitis (EoE). Upon completion of this activity, participants should be better able to: Specify the current guideline recommendations for the pharmacologic treatment of eosinophilic esophagitis (EoE); Formulate personalized strategies to use approved pharmacologic options during initiation and maintenance phases of EoE management; and Apply multidisciplinary strategies to optimize long-term management of patients with EoE using approved pharmacologic treatments.

Please visit answersincme.com/860/103760795-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Keith C. Ferdinand, MD; Mike Sharma, MD, MSc; and Eddie Needham, MD, FAAFP. In this activity, experts in atrial fibrillation (AF) discuss evidence-based strategies to optimize stroke prevention, address anticoagulation gaps in clinical practice, and prepare for emerging approaches to anticoagulation. Upon completion of this activity, participants should be better able to: Apply evidence-based risk stratification tools and guidelines to address anticoagulation gaps in primary care patients with AF; Assess the clinical impact of suboptimal anticoagulation on AF stroke prevention; Evaluate emerging strategies for AF stroke prevention, including factor XI/XIa inhibitors; and Outline multidisciplinary, equity-focused care strategies incorporating social determinants to optimize AF stroke prevention in diverse populations.

Please visit answersincme.com/XUG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sara A. Hurvitz, MD, FACP. In this activity, an expert in breast cancer discusses the evidence for TROP2-directed antibody-drug conjugates in metastatic triple-negative disease (mTNBC). Upon completion of this activity, participants should be better able to: Review the clinical impact of TROP2-directed antibody-drug conjugates (ADCs) for the management of mTNBC; Evaluate the clinical implications of the evidence exploring first-line use of TROP2 ADCs in combination with immunotherapy for mTNBC; and Develop an evidence-informed strategy that incorporates TROP2-directed ADCs and immunotherapy combinations into first-line management of mTNBC, where appropriate.

Please visit answersincme.com/GFY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vishal A. Patel, MD; and Jonathan S. Zager, MD, FACS, FSSO. In this activity, experts in cutaneous oncology discuss the evolving role of gene expression profiling (GEP) tests in refining risk assessment and supporting individualized, multidisciplinary management strategies for patients with melanoma. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using GEP tests to stratify the risk of disease progression in patients with cutaneous melanoma; Review the clinical evidence, including guideline-supported data, for GEP tests to stratify disease progression risk in patients with cutaneous melanoma; Formulate multidisciplinary strategies for incorporating the results of GEP tests into risk-based management of patients with cutaneous melanoma; and Outline patient-centered approaches to integrating GEP tests into the management of patients with cutaneous melanoma at risk of metastasis.

Please visit answersincme.com/860/2026-MC-001884-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Marc Serota, MD; Kristin Sokol, MD, MS, MPH; and Michelle Tarbox, MD. In this activity, experts in chronic spontaneous urticaria (CSU) discuss strategies to reduce diagnostic delays and how to personalize care beyond antihistamines. Upon completion of this activity, participants should be better able to: Recognize the impact of delayed diagnosis on disease control in patients with CSU; Review key inflammatory pathways—including type 2 inflammation—in CSU pathogenesis and how targeted therapies modulate them; Assess the latest clinical data for targeted therapies for the treatment of CSU; and Apply evidence-based strategies to personalize the management of antihistamine-refractory CSU.

Please visit answersincme.com/860/101834101-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Simpa S. Salami, MD, MPH; and Neal D. Shore, MD, FACS. In this activity, experts in prostate cancer discuss new evidence for individualized, evidence-based treatment strategies in metastatic hormone-sensitive disease. Upon completion of this activity, participants should be better able to: Evaluate the clinical implications of the most recent data informing the standard of care treatment options for mHSPC; Integrate patient-, disease-, and therapy-related factors to develop individualized, evidence-based treatment strategies for mHSPC; and Design patient-centered care approaches that balance the benefit and risk of treatment to optimize outcomes in mHSPC.

Please visit answersincme.com/ZPW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by David R. Staskin, MD. In this activity, an expert in urology discusses strategies to diagnose and individualize treatment for overactive bladder (OAB) in patients with benign prostatic hyperplasia (BPH), including the role of beta-3 adrenergic agonists and guideline-based care. Upon completion of this activity, participants should be better able to: Identify strategies to diagnose overactive bladder (OAB) in patients with benign prostatic hyperplasia (BPH); Assess the evidence for beta-3 adrenergic agonists in the treatment of OAB among patients with BPH; and Outline approaches to tailor OAB treatment for individual patients with BPH.

Please visit answersincme.com/TNM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Richard Kim, MD. In this activity, an expert in oncology discusses when and how to sequence later-line and chemotherapy-free therapies in metastatic colorectal cancer (mCRC). Upon completion of this activity, participants should be better able to: Evaluate factors influencing a treatment switch from cytotoxic agents for patients with stable metastatic colorectal cancer (mCRC); Formulate practical approaches for transitioning from chemotherapy to tyrosine kinase inhibitor (TKI) treatment in later-line settings for patients with mCRC; and Describe strategies to prolong chemotherapy-free disease control with TKIs.

Please visit answersincme.com/KJW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aman Chauhan, MD and Rhonda K. Yantiss, MD. In this activity, experts in medical oncology and pathology discuss identification and treatment of extrapulmonary neuroendocrine carcinomas and extrapulmonary neuroendocrine tumors. Upon completion of this activity, participants should be better able to: Differentiate extrapulmonary neuroendocrine carcinoma (EP-NEC) from extrapulmonary neuroendocrine tumors (EP-NETs); Identify diagnostic and pathological approaches to improve the recognition and accurate classification of EP-NEC and EP-NET; Evaluate emerging clinical data on DLL3-targeting bispecific TCE agents in the treatment of EP-NEC and EP-NET; and Formulate evidence-based strategies to integrate DLL3-targeting bispecific TCE therapies into evolving treatment paradigms for EP-NEC and EP-NET.

Please visit answersincme.com/BJN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Rajesh Gandhi, MD. In this activity, an expert in infectious diseases discusses novel oral antiretroviral therapy (ART) for the management of human immunodeficiency virus (HIV). Upon completion of this activity, participants should be better able to: Recognize the rationale for novel oral ART regimens in the management of virologically suppressed HIV infection; Review the clinical impact of novel emerging oral ART regimens for patients with virologically suppressed HIV infection; and Formulate patient-centered strategies for optimizing the personalized management of oral ART for patients with virologically suppressed HIV infection.

Please visit answersincme.com/DDT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Robert Haddad, MD. In this activity, an expert in medical oncology discusses locally advanced head and neck squamous cell carcinoma (LA HNSCC). Upon completion of this activity, participants should be better able to: Discuss the clinical implications of the latest data for approved and recommended regimens for resectable LA HNSCC in the pre- and postoperative settings; Outline strategies to integrate immunotherapy into pre- and postoperative settings for resectable LA HNSCC, in the context of conventional treatment; and Apply multidisciplinary team approaches to effectively manage patients with LA HNSCC across pre- and postoperative treatment phases.

Please visit answersincme.com/860/103093269-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Stephanie Faubion, MD, MBA, FACP, MSCP and Shelby Harris, PsyD, CBSM, DBSM. In this activity, experts in menopause discuss diagnosis and management of sleep disturbances due to vasomotor symptoms. Upon completion of this activity, participants should be better able to: Recognize the burden of menopause-related VMS occurring during sleep; Explain the clinical significance of the latest data for novel non-hormonal pharmacotherapies in the treatment of menopause-related VMS, including those occurring during sleep; Identify patients with menopause-related VMS and sleep disturbances who may benefit from a non-hormonal pharmacotherapy approach; and Formulate patient-centered management plans to enhance outcomes for patients with menopause-related VMS and sleep disturbances.

Please visit answersincme.com/RAH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alan G. Kaplan, MD, CCFP(EM), FCFP, CPC(HC); Sherilyn Houle, BSP, PhD, CTH, AFTM RCPS(Glasg), FISTM; and Aakash Modi, MD, CFPC, ABFM, FAAFP. In this activity, two experts in adult pneumococcal disease immunization discuss strategies to close the prevention gap in primary care and pharmacy practice. Upon completion of this activity, participants should be better able to: Describe the burden of adult pneumococcal disease in Canada, including the role of the aging immune system; Recognize opportunities for primary care physicians and pharmacists to collaborate to improve disease prevention in adults at risk for invasive pneumococcal disease; and Apply current Canadian pneumococcal vaccination recommendations into adult patient care.

Please visit answersincme.com/TNH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nick H. Kim, MD and Vallerie V. McLaughlin, MD. In this activity, experts in cardiovascular medicine and pulmonology discuss pulmonary arterial hypertension (PAH). Upon completion of this activity, participants should be better able to: Recognize the importance of treatment escalation for appropriate patients with PAH; Design risk-based treatment escalation plans for patients with PAH; Review the clinical impact of guideline-recommended therapies for risk-based treatment escalation in PAH; and Propose practical considerations to enhance outcomes for patients with PAH requiring treatment escalation.

Please visit answersincme.com/FAJ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nancy L. Kuntz, MD; Vanessa Battista, DNP, MBA, CPNP-PC, CHPPN, FPCN, FAAN; and Ethan Hilgert. In this activity, experts in the management of spinal muscular atrophy (SMA) discuss the diagnosis and treatment of late-onset SMA (type 3b, 4) in adults. Upon completion of this activity, participants should be better able to: Recognize clinical features that are suggestive of SMA in adults; Review the evidence for approved disease-modifying therapies in adult patients with SMA; and Apply strategies that address barriers to achieving optimal clinical outcomes in adults with SMA.

Please visit answersincme.com/GXT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sarah Donahue, MPH, ANP, AOCNP. In this activity an expert in breast cancer discusses the efficacy and safety of oral SERDs in HR+, HER2- advanced breast cancer. Upon completion of this activity, participants should be better able to: Review the evidence-based use of oral SERDs in the treatment plan for patients with HR+, HER2- advanced breast cancer; Specify the key roles of nurses and NPs in optimizing the overall care for patients with HR+, HER2- advanced breast cancer who are candidates for oral SERDs; and Outline a multidisciplinary treatment plan to maximize the long-term care of patients with HR+, HER2- advanced breast cancer.

Please visit answersincme.com/860/240201346-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Shannon Salvador, MD, MSc, FRCSC; Sheila Wijayasinghe, MD, CCFP, MSCP; and Christine Palmay, HBArtSci, MD, CCFP. In this activity, experts in HPV vaccination discuss its critical role in cancer prevention, the latest guideline updates, and strategies to improve uptake in populations of interest. Upon completion of this activity, participants should be better able to: Describe the prevalence and impact of human papilloma virus (HPV) infection and its associated cancers across diverse patient populations; Explain the rationale for HPV vaccination in adolescents, including the role of publicly funded programs and current uptake trends in Canada; Explain the rationale for HPV vaccination beyond adolescence, including benefits for adults, men, and individuals in monogamous relationships; and Apply current HPV vaccination recommendations and interprofessional strategies to build confidence and improve uptake across care settings, including cervical cancer screening visits.

Please visit answersincme.com/MRQ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alexandra K. Golant, MD; Peter Lio, MD, FAAD; and Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP. In this activity, experts in dermatology discuss the OX40L pathway and its potential role in the treatment of moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Identify the rationale for targeting the OX40/OX40 ligand (OX40L) pathway in the treatment of moderate-to-severe atopic dermatitis (AD); Assess the evidence on efficacy outcomes and safety profiles of the emerging OX40/OX40L inhibitors in AD, including quality of life (QoL) impact; Integrate QoL assessments into shared decision-making with patients who have moderate or severe AD; and Outline strategies for enhancing the multidisciplinary management of moderate-to-severe AD.

Please visit answersincme.com/UMW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jeffrey Neul, MD, PhD. n this activity, an expert in pediatrics and neurology discusses the latest data for treatment of Rett syndrome. Upon completion of this activity, participants should be better able to: Discuss the latest efficacy and safety data for investigational neuroactive pharmacologic therapies in the treatment of RTT; and Translate the latest data into treatment considerations for approved and emerging therapies in RTT.

Please visit answersincme.com/CNW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Stephen V. Liu, MD and Amber Fake. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses the evolving patient-centered management of HER2-mutant NSCLC, focusing on the use of HER2-targeted TKIs. Upon completion of this activity, participants should be better able to: Describe how HER2-targeted TKIs may address the clinical needs for diverse patient populations with HER2-mutant NSCLC; Implement evidence-based molecular profiling to identify HER2 alterations in NSCLC; Evaluate the clinical evidence of current and emerging HER2-targeted treatments; and Integrate shared decision-making strategies to align preferences for patients with HER2-mutant NSCLC.

Please visit answersincme.com/860/IME_2025_00012595-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John V. Heymach, MD, PhD; and Mark Awad, MD, PhD. In this activity, experts in oncology discuss the role of dual and HER2-selective oral tyrosine kinase inhibitors in patients with HER2-mutated non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Specify how TKIs may address unmet therapeutic needs for diverse patient populations with HER2-mutated NSCLC; Interpret the clinical evidence for approved oral TKIs for patients with HER2-mutated NSCLC; and Assess which patients may be candidates for approved oral HER2-targeting TKIs in the context of the current standard of care.

Please visit answersincme.com/860/240201372-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jeffrey Habert, MD, CCFP, FCFP and Maria Anton, RPh, BSc, PharmD. In this activity, experts in type 2 diabetes discuss guideline-recommended goals of treatment and strategies to develop personalized plans that incorporate the latest GLP-1–based therapies. Upon completion of this activity, participants should be better able to: Propose guideline-recommended goals of treatment for adults with T2D; Formulate personalized, evidence-based treatment plans for T2D; and Apply practical strategies for the initiation and integration of contemporary therapies for adults with T2D.

Please visit answersincme.com/860/101385133-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Peter A. Fasching, MD; Michael Gnant, MD, FACS; and Cristina Saura Manich, MD, PhD. In this activity, experts in breast cancer discuss new evidence in neoadjuvant and adjuvant care of early disease. Upon completion of this activity, participants should be better able to: Describe multidisciplinary viewpoints on the role that HER2-directed ADCs may play in the (neo)adjuvant setting for HER2-positive early-stage breast cancer; Evaluate evidence for the (neo)adjuvant use of HER2-directed ADCs in the multidisciplinary management of HER2-positive early-stage breast cancer; and Formulate evidence-based multidisciplinary strategies to optimally incorporate (neo)adjuvant HER2-directed ADCs into the treatment paradigm for HER2-positive early-stage breast cancer.

Please visit answersincme.com/CKX860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prithviraj Bose, MD. In this activity, an expert in hematology discusses the role of current and emerging treatment options for patients living with advanced systemic mastocytosis. Upon completion of this activity, participants should be better able to: Identify prognostic features of advanced systemic mastocytosis (AdvSM) that guide diagnosis and care planning; Describe current and emerging treatment options for patients with AdvSM; and Evaluate patient- and disease-related strategies that inform treatment selection in AdvSM.

Please visit answersincme.com/YVT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Michael Mak, MD, FRCPC, DRCPSC, FCPA, FAPA, FAASM; and Sabrina Kwon, BSc, MD. In this activity, experts in sleep and primary care discuss strategies for the screening, diagnosis, and treatment of adults with obesity and obstructive sleep apnea. Upon completion of this activity, participants should be better able to: Recognize key clinical and diagnostic challenges in identifying obstructive sleep apnea (OSA) in adults with obesity; Evaluate the role of weight management strategies, including incretin-based therapies, in the comprehensive management of OSA in adults with obesity; and Apply practical, patient-centered approaches to optimize obesity and OSA management across the care pathway.